We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CBER Plans New Intermediate Pathway for Cell and Gene Therapies
CBER Plans New Intermediate Pathway for Cell and Gene Therapies
The FDA is soon to explore new “intermediate” approval pathways that might be more appropriate for certain cellular and gene therapy products than the regulatory pathways they face now.